About Acyl-coenzyme A thioesterase 6
Acyl-coenzyme A thioesterase 6 (ACOT6) is a protein
from Homo sapiens identified by UniProt accession
Q3I5F7, 421 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | Acyl-coenzyme A thioesterase 6 |
| UniProt accession | Q3I5F7 |
| Gene | ACOT6 |
| Organism | Homo sapiens |
| Length | 421 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (18)
Diseases linked to this target (Open Targets).
- reticulocyte count · score 0.24
- leukocyte count · score 0.16
- urinary metabolite measurement · score 0.09
- mean corpuscular hemoglobin · score 0.08
- mean corpuscular hemoglobin concentration · score 0.07
- glomerular filtration rate · score 0.06
- hypouricemia, renal, 2 · score 0.04
- platelet component distribution width · score 0.04
- familial juvenile hyperuricemic nephropathy type 1 · score 0.04
- xanthinuria type II · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q3I5F7-F1 | alphafold | PREDICTED | 94.96 | — |
Amino-acid sequence (421 residues)
MAATLILEPA GRCCWDEPLR IAVRGLAPEQ PVTLRTSLRD EEGALFRAHA RYRADARDEL DLERAPALGG SFAGLQPMGL LWALEPEKAL VRLVKRDVRT PFAVELEVLD GHDTEPGRLL CLAQNKRDFL RPGVRREPVR AGPVRAALFL PPDEGPFPGI IDLFGSSRGL CEYRASLLAG HGFAVLALAY FRFEDLPEDL NDVHLEYFEE AVDFMLQHPK VKGPSIALLG FSKGGDLCLS MASFLKGITA TVLINACVAN TVAPLHYKDM IIPKLVDDLG KVKITKSGFL TFMDTWSNPL EEHNHQSLVP LEKAQVPFLF IVGMDDQSWK SEFYAQIASE RLQAHGKERP QIICYPETGH CIDPPYFPPS RASVHAVLGE AIFYGGEPKA HSKAQVDAWQ QIQTFFHKHL NGKKSVKHSK I
Explore Acyl-coenzyme A thioesterase 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets